Form D · Biotechnology

CND Life Sciences, Inc.

Scottsdale, AZ · CIK 0001841099

Offering snapshot reported Aug 3, 2026 · SEC filing

Reported sold
$6.32M
Offering amount: $6.32M
Investors reported
14
Form D · investor count
Minimum accepted
$25K
Reported outside-investor minimum
First sale
Jun 9, 2026
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$3.16M$6.32MJun 16, 2026: $4,314,750.00Jun 16, 2026Aug 3, 2026: $6,316,514.00Aug 3, 2026

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$4,314,750 → $6,316,514
  • Reported investors1 → 14

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 3, 2026Amendment$6,316,514$2,001,764vs Jun 16, 202614SEC filing
Jun 16, 2026Initial$4,314,750No comparison1SEC filing
May 6, 2025Amendment$8,648,469$5,133,904vs Mar 6, 202538SEC filing
Apr 15, 2025Amendment$3,664,565$150,000vs Mar 6, 202527SEC filing
Mar 6, 2025Initial$3,514,565No comparison26SEC filing
Mar 27, 2024Initial$2,007,000No comparison22SEC filing
Jul 24, 2023Initial$1,457,000No comparison19SEC filing
Mar 24, 2023Amendment$4,500,000$1,955,000vs Sep 22, 202226SEC filing
Sep 22, 2022Initial$2,545,000No comparison17SEC filing
Nov 10, 2021Initial$4,200,000No comparison22SEC filing
Apr 28, 2021Amendment$2,875,000$2,050,000vs Jan 20, 202120SEC filing
Jan 20, 2021Initial$825,000No comparison7SEC filing

Offering details

Securities
Debt
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-587487

Source: Form D, filed Aug 3, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Enrique Carrazana Director
Roy Freeman Director
Christopher Gibbons Director
Peter Harris Director, Executive
Todd Levine Director, Executive
Richard J. Morello Director, Executive
Jack Seaver Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
9165 E. Del Camino Drive Suite 101
Scottsdale, AZ, 85258-4381
Phone: 617-223-1585